<code id='DDE4B7F225'></code><style id='DDE4B7F225'></style>
    • <acronym id='DDE4B7F225'></acronym>
      <center id='DDE4B7F225'><center id='DDE4B7F225'><tfoot id='DDE4B7F225'></tfoot></center><abbr id='DDE4B7F225'><dir id='DDE4B7F225'><tfoot id='DDE4B7F225'></tfoot><noframes id='DDE4B7F225'>

    • <optgroup id='DDE4B7F225'><strike id='DDE4B7F225'><sup id='DDE4B7F225'></sup></strike><code id='DDE4B7F225'></code></optgroup>
        1. <b id='DDE4B7F225'><label id='DDE4B7F225'><select id='DDE4B7F225'><dt id='DDE4B7F225'><span id='DDE4B7F225'></span></dt></select></label></b><u id='DDE4B7F225'></u>
          <i id='DDE4B7F225'><strike id='DDE4B7F225'><tt id='DDE4B7F225'><pre id='DDE4B7F225'></pre></tt></strike></i>

          hotspot

          hotspot

          author:hotspot    Page View:6
          Adam's take main illustration
          Molly Ferguson/STAT

          This week, a preview of the TUDCA study in ALS and thoughts on how it might impact Amylyx Pharmaceuticals. Also, I chatted with CRISPR Therapeutics CEO Sam Kulkarni about its new investor. Read to the end for some burning questions, random thoughts.

          The next ALS data readout — overdue but important

          A European academic consortium is expected to announce results soon from a clinical trial investigating the use of a widely available nutritional supplement called tauroursodeoxycholic acid, or TUDCA, in people living with ALS. The outcome of the TUDCA-ALS study could have implications for Amylyx Pharmaceuticals, because TUDCA is one of the two main ingredients in Relyvrio, the company’s approved drug for ALS.

          advertisement

          In a recent interview at Amylyx’s Kendall Square headquarters, co-CEOs Justin Klee and Josh Cohen mostly downplayed the suggestion that results from the randomized, placebo-controlled TUDCA study might affect Relyvrio negatively, or even positively.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          comprehensive

          Walensky prepares to leave CDC — and Congress — behind
          Walensky prepares to leave CDC — and Congress — behind

          OutgoingCDCDirectorRochelleWalenskyJIMWATSON/AFPviaGettyImagesRochelleWalensky,theoutgoingdirectorof

          read more
          Results on Novartis prostate cancer therapy could expand its use
          Results on Novartis prostate cancer therapy could expand its use

          TheNovartisboothatESMO2023inMadrid.AndrewJoseph/STATMADRID—ResultspresentedMondaycouldexpandtheuseof

          read more
          State Dept. review finds Biden bears some blame for Afghanistan failures
          State Dept. review finds Biden bears some blame for Afghanistan failures

          3:53HundredsofpeoplegathernearaU.S.AirForceC-17transportplaneattheperimeteroftheinternationalairport

          read more

          Why a market frenzy over new weight loss drugs defies logic

          ChristineKao/STATThere’saspecterhauntingWallStreet.Itstartedinbiotech,wherecompaniesmakingdrugsforth